Browse by Audience
The anti-inflammatory and analgesic drugs currently used are associated with several adverse effects and found to be highly unsafe for long-term use. Currently, nineteen novel bis-Schiff base derivatives (1-19) of […]
Learn More >Impaired branched-chain amino acid (BCAA) catabolism has recently been implicated in the development of mechanical pain, but the underlying molecular mechanisms are unclear. Here, we report that defective BCAA catabolism […]
Learn More >The mechanism of pain symptoms in Parkinson’s disease (PD) is unclear. Norepinephrine (NE) regulates neuropathic pain through ascending and descending pathways. However, the loss of NE neurons in the brain […]
Learn More >Activated G-protein-coupled receptor 39 (GPR39) has been shown to attenuate inflammation by interacting with sirtuin 1 (SIRT1) and peroxisome proliferator-activated receptor-γ coactivator 1α (PGC-1α). However, whether GPR39 attenuates neuropathic pain […]
Learn More >Thousand and one amino acid kinase 2 (TAOK2) is a member of the mammalian sterile 20 kinase family and is implicated in neurodevelopmental disorders; however, its role in neuropathic pain […]
Learn More >Itch can be reduced by pain. Activation of sleeping nociceptors (CMi) is a crucial mechanism for the peripheral component of intense and long-lasting pain. Thus, activation of CMi might be […]
Learn More >We have previously reported elevated levels of the complement lectin pathway proteins L-ficolin and H-ficolin in axial spondyloarthritis (axSpA) patients compared with healthy controls. The aim of this study was […]
Learn More >Exposure to alcohol during adolescence produces many effects that last well into adulthood. Acute alcohol is analgesic and people living with pain report drinking alcohol to reduce pain, but chronic […]
Learn More >Chronic wounds adversely affect quality of life. Pain is associated with chronic wounds, and its impact can vary according to wound aetiology, condition, and patient factors. This systematic review examined […]
Learn More >
Adverse event profile of CGRP monoclonal antibodies: findings from the FDA adverse event reporting database.
Four CGRP Monoclonal Antibodies (mAbs) have been approved for migraine prophylaxis by the Food and Drug Administration (FDA) since 2018. However, there are concerns about the safety of these four […]
Learn More >